default mode network – Page 2

Biological markers of treatment response to serotonergic psychedelic therapies: a systematic review

mycolabadmin

This review examines how scientists can predict which patients will benefit most from psychedelic-assisted therapy for depression by measuring biological markers in the brain and blood. Researchers found that certain brain changes and protein levels—particularly involving the amygdala, specific brain regions, and inflammation markers—appear linked to treatment success. While the current studies are small, they suggest that measuring these biological markers could eventually help doctors personalize psychedelic treatments for depression.

Therapeutic emergence of dissociated traumatic memories during psilocybin treatment for anorexia nervosa

mycolabadmin

Two patients with severe anorexia nervosa received psilocybin-assisted therapy and unexpectedly recovered memories of sexual assault that had been unconsciously suppressed. Processing these traumatic memories with professional support led both patients to achieve remission from their eating disorders within three months. This case report suggests that psilocybin may help unlock and heal deeply buried trauma underlying eating disorders, though more research is needed to understand how this works and ensure patient safety.

The central role of the Thalamus in psychosis, lessons from neurodegenerative diseases and psychedelics

mycolabadmin

This paper explores how the thalamus, a key brain structure controlling attention and perception, malfunctions in Parkinson’s disease and similar neurological conditions, causing hallucinations and delusions. Interestingly, these symptoms resemble the altered mental states produced by psychedelic drugs like LSD and psilocybin. By studying both conditions together, researchers found that a common mechanism called thalamocortical dysrhythmia disrupts how the brain filters information and processes reality, offering new insights for treating psychotic symptoms.

Psilocybin, an Effective Treatment for Major Depressive Disorder in Adults – A Systematic Review

mycolabadmin

Psilocybin, a naturally occurring compound found in certain mushroom species, shows significant promise as a treatment for depression. Clinical studies reviewed in this research found that psilocybin-assisted therapy reduced depressive symptoms in every patient studied, with improvements lasting months after treatment. Unlike traditional antidepressants, psilocybin caused only mild temporary side effects and worked faster, suggesting it could become an important alternative treatment for depression.

The effect of psilocybin on empathy and prosocial behavior: a proposed mechanism for enduring antidepressant effects

mycolabadmin

This review examines how psilocybin may help treat depression by increasing empathy and prosocial behavior. While psilocybin leaves the body within hours, its antidepressant effects can last months, and researchers believe empathy and helping others may explain this lasting benefit. The authors suggest psilocybin starts a positive cycle where increased empathy leads to helping others, which boosts mood and well-being, which further reinforces empathetic behavior.

Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial

mycolabadmin

This study tests whether psilocybin (the active compound in certain mushrooms) can help people with obsessive-compulsive disorder who haven’t responded to standard treatments. In a carefully controlled trial, participants receive either a single dose of psilocybin or a placebo while receiving psychological support, with their brain activity and symptoms monitored. The research aims to determine if this novel treatment is safe and whether it could work faster than existing medications for this difficult-to-treat condition.

Exploring neural markers of dereification in meditation based on EEG and personalized models of electrophysiological brain states

mycolabadmin

Researchers developed a new brain-monitoring technique called the Inner Dereification Index that can detect when someone is meditating versus mind-wandering using only a brief EEG recording. By analyzing electrical activity in specific brain regions involved in self-awareness and personal thoughts, the method can accurately track meditation progress in real-time with 99.6% accuracy. The technique works with minimal training data and shows that certain meditation practices—particularly Tibetan Buddhist techniques aimed at experiencing the emptiness of self—create distinctive brain patterns. This breakthrough could enable real-time meditation feedback devices and personalized meditation guidance.

Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression

mycolabadmin

This research study is investigating how psilocybin, a compound from certain mushrooms, affects the brain in people with depression. The study involves 50 participants who will receive either psilocybin or a placebo, with their brain activity monitored using advanced imaging scans. Researchers will examine how psilocybin changes blood flow and network activity in brain regions involved in mood regulation, and whether these changes are linked to improvements in depression symptoms.

Neural mechanisms underlying psilocybin’s therapeutic potential – the need for preclinical in vivo electrophysiology

mycolabadmin

Psilocybin, the active compound in magic mushrooms, shows promise for treating depression and other mental health conditions. This review examines how psilocybin works in the brain, particularly by affecting brain regions involved in self-reflection and emotion regulation. The authors argue that new brain recording techniques are needed to fully understand how psilocybin produces its beneficial effects, which could help improve treatments for people with severe depression.

PsilOCD: A Pharmacological Challenge Study Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity

mycolabadmin

This study is investigating whether psilocybin (an active compound in magic mushrooms) can help people with obsessive-compulsive disorder (OCD) by improving their mental flexibility and brain plasticity. Participants will receive two doses of psilocybin—a low test dose and a slightly higher therapeutic dose—four weeks apart, while receiving professional psychological support. Researchers will measure changes in cognitive abilities and brain activity to understand how psilocybin might help reduce OCD symptoms like intrusive thoughts and repetitive behaviors.

Research Keyword: default mode network